Sen-Jam Pharmaceutical, a developer of precision remedies to address chronic inflammation and metabolic disorders, announced on Tuesday that it has received ethics approval for a clinical trial of its flagship asset, SJP-001, in Australia.
The trial is intended to assess the the efficacy and safety of SJP-001, an over-the-counter therapeutic targeting metabolic health and relief from overindulgence in food and drink, including its effects on inflammatory pathways.
This milestone paves the way for the product to advance through clinical evaluation, with the trial carried out by Nucleus Network, an Australian early-phase clinical research organisation, and supported by contract research organisation Novotech.
The SJP-001 clinical trial is designed to assess the product's ability to modulate inflammation and improve metabolic outcomes, providing relief from the after effects of dietary overindulgence while supporting long-term metabolic health.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval